The University of Bergen (UiB) is a modern research driven university with 16900 students and 3700 staff. The university comprises 7 faculties spanning 54 departments, institutes and interdisciplinary research centres. UiB is the most cited university in Norway. The Influenza Centre is situated in a state-of-the-art laboratory building, at the University of Bergen and Haukeland University Hospital with the vision of reducing the global burden of influenza illness through being an international leader in development of new and improved influenza vaccines. The Centre specializes in preclinical (immunogenicity and protective efficacy) studies and human clinical phase I-IV trials of new influenza vaccines under good clinical practice (GCP).
Main roles in project
The key competence of the Influenza Centre at the University of Bergen is human clinical trials of influenza and COVID-19 vaccines focusing on immunology particularly B- and T-cells. The University of Bergen will be responsible for conducting the proposed phase IV trial in young children and serological evaluation of vaccine responses. We will also be involved in technology transfer of serological assays to India.
This project has received funding from the European Union H2020 (grant no. 874866) and the Dept. of Biotechnology, Govt. of India (project no. BT/IN/EU-INF/16/AP/19-20/11746)